Focused On-demand Library for Eukaryotic initiation factor 4A-III

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

PARTNER
Receptor.AI
 
UPACC
P38919

UPID:
IF4A3_HUMAN

ALTERNATIVE NAMES:
ATP-dependent RNA helicase DDX48; ATP-dependent RNA helicase eIF4A-3; DEAD box protein 48; Eukaryotic initiation factor 4A-like NUK-34; Eukaryotic translation initiation factor 4A isoform 3; Nuclear matrix protein 265

ALTERNATIVE UPACC:
P38919; Q15033; Q6IBQ2; Q96A18

BACKGROUND:
The protein EIF4A3, also known as ATP-dependent RNA helicase eIF4A-3, is integral to mRNA splicing as part of the spliceosome and the exon junction complex (EJC). It modulates the fate of mRNAs post-splicing, affecting their export, localization, and translation. EIF4A3's RNA helicase activity is crucial for its function in gene expression regulation.

THERAPEUTIC SIGNIFICANCE:
Mutations in EIF4A3 cause Richieri-Costa-Pereira syndrome, featuring distinct craniofacial and limb abnormalities. The exploration of EIF4A3's function offers promising avenues for developing targeted therapies for this and potentially other genetic disorders involving mRNA processing.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 8777 of 8789